Literature DB >> 9040656

A longitudinal study comparing thenar motor unit number estimates to other quantitative tests in patients with amyotrophic lateral sclerosis.

K J Felice1.   

Abstract

The following data were obtained on 21 amyotrophic lateral sclerosis (ALS) patients, aged 36-76 years (mean: 58 years), at baseline and months 4, 8, and 12: thenar motor unit number estimate (MUNE) using multiple point stimulation, mean thenar surface-recorded motor unit action potential negative-peak area, thenar compound muscle action potential amplitude, isometric hand grip strength, total Medical Research Council (MRC) manual muscle testing score, Appel ALS rating scale, and forced vital capacity (FVC). The absolute mean rate of change per month was significantly greater (P < 0.01) for MUNE values than for MRC and FVC values in the 21 ALS patients. In a subset of patients (n = 6) with slowly progressive disease, the absolute mean rate of change per month was significantly greater (P < 0.01) for MUNE values than for all other test values. In addition, MUNE values were the most sensitive index for documenting changes in disease progression over time.

Entities:  

Mesh:

Year:  1997        PMID: 9040656     DOI: 10.1002/(sici)1097-4598(199702)20:2<179::aid-mus7>3.0.co;2-9

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  25 in total

1.  Techniques and applications of EMG: measuring motor units from structure to function.

Authors:  Rachel C Thornton; Andrew W Michell
Journal:  J Neurol       Date:  2012-01-25       Impact factor: 4.849

Review 2.  Measures and markers in amyotrophic lateral sclerosis.

Authors:  Merit Cudkowicz; Muhammad Qureshi; Jeremy Shefner
Journal:  NeuroRx       Date:  2004-04

3.  Multipoint incremental motor unit number estimation as an outcome measure in ALS.

Authors:  J M Shefner; M L Watson; L Simionescu; J B Caress; T M Burns; N J Maragakis; M Benatar; W S David; K R Sharma; S B Rutkove
Journal:  Neurology       Date:  2011-06-15       Impact factor: 9.910

Review 4.  Challenges in the Understanding and Treatment of Amyotrophic Lateral Sclerosis/Motor Neuron Disease.

Authors:  Jeffrey Rosenfeld; Michael J Strong
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 5.  Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis.

Authors:  Seward B Rutkove
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 6.  The "dying-back" phenomenon of motor neurons in ALS.

Authors:  Michal Dadon-Nachum; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2010-11-07       Impact factor: 3.444

Review 7.  ALS biomarkers for therapy development: State of the field and future directions.

Authors:  Michael Benatar; Kevin Boylan; Andreas Jeromin; Seward B Rutkove; James Berry; Nazem Atassi; Lucie Bruijn
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

8.  Pre-symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1(G93A) ALS mouse model.

Authors:  C R Hayworth; F Gonzalez-Lima
Journal:  Neuroscience       Date:  2009-08-20       Impact factor: 3.590

Review 9.  Assessment of Motor Units in Neuromuscular Disease.

Authors:  Robert D Henderson; Pamela A McCombe
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

10.  Motor unit number estimation in the rat tail using a modified multipoint stimulation technique.

Authors:  Lora J Kasselman; Jeremy M Shefner; Seward B Rutkove
Journal:  Muscle Nerve       Date:  2009-07       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.